Shots:

• Thermo Fischer acquires Brammer Bio- in all stock transaction for $1.7B in cash with its viral vector manufacturing techniques in gene and cell therapies. The transaction is expected to close in Q2’19
• The focus of the acquisition is to expand Thermo’s footprints in gene and cell therapy market combining Brammer’s viral vector technology within multiple genetic disorders
• Brammer’s CGMP (Current Good Manufacturing Practices) gene therapy techniques includes testing and manufacturing of viral vectors for in vivo and ex vivo clinical applications

Click here to read full press release/ article | Ref: Thermofisher Scientific | Image: VirtualStudio